Aart Jochemsen
- Naam
- Dr. A.G. Jochemsen
- Telefoon
- +31 71 526 9111
- a.g.jochemsen@lumc.nl
- Faculteit Geneeskunde
- Divisie 4
- Cel en Chemische biologie
- Heijkants, R.C.; Teunisse, A.F.A.S.; Jong, D. de; Glinkina, K.; Mei, H.L.; Kielbasa, S.M.; Szuhai, K. & Jochemsen, A.G. (2022), MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells, Cancers 14(18).
- Mejia-Hernandez, J.O.; Raghu, D.; Caramia, F.; Clemons, N.; Fujihara, K.; Riseborough, T.; Teunisse, A.; Jochemsen, A.G.; Abrahmsen, L.; Blandino, G.; Russo, A.; Gamell, C.; Fox, S.B.; Mitchell, C.; Takano, E.A.; Byrne, D.; Miranda, P.J.; Saleh, R.; Thorne, H.; Sandhu, S.; Williams, S.G.; Keam, S.P.; Haupt, Y. & Haupt, S. (2022), Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status, Cancers 14(16).
- Glinkina, K.; Groenewoud, A.; Teunisse, A.F.A.S.; Snaar-Jagalska, B.E. & Jochemsen, A.G. (2022), Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen, Cancers 14(13).
- Prunier, C.; Alay, A.; Dijk, M. van; Ammerlaan, K.L.; Gelderen, S. van; Marvin, D.L.; Teunisse, A.; Slieker, R.C.; Szuhai, K.; Jochemsen, A.G.; Sole, X.; Dijke, P. ten & Ritsma, L. (2021), Breast cancer dormancy is associated with a 4NG1 state and not senescence, npj Breast Cancer 7(1).
- Souri, Z.; Jochemsen, A.G.; Wierenga, A.P.A.; Kroes, W.G.M.; Verdijk, R.M.; Velden, P.A. van der; Luyten, G.P.M. & Jager, M.J. (2021), Expression of HDACs 1, 3 and 8 Is upregulated in the presence of Infiltrating lymphocytes in uveal melanoma, Cancers 13(16).
- Souri, Z.; Jochemsen, A.G.; Versluis, M.; Wierenga, A.P.A.; Nemati, F.; Velden, P.A. van der; Kroes, W.G.M.; Verdijk, R.M.; Luyten, G.P.M. & Jager, M.J. (2020), HDAC inhibition increases HLA class I expression in uveal melanoma, Cancers 12(12).
- Christodoulou, E.; Rashid, M.; Pacini, C.; Droop, A.; Robertson, H.; Groningen, T. van; Teunisse, A.F.A.S.; Iorio, F.; Jochemsen, A.G.; Adams, D.J. & Doorn, R. van (2020), Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma, Pigment Cell & Melanoma Research 34(1).
- Mamunur Rashid, Clare Pacini, Droop Alastair, Holly Robertson, Francesco Iorio & David J. Adams (2020), Analysis of CRISPR‐Cas9 screens identifies genetic dependencies in melanoma, Pigment Cell & Melanoma Research.
- Wohlberedt, K.; Klusmann, I.; Derevyanko, P.K.; Henningsen, K.; Choo, J.A.M.Y.; Manzini, V.; Magerhans, A.; Giansanti, C.; Eischen, C.M.; Jochemsen, A.G. & Dobbelstein, M. (2020), Mdm4 supports DNA replication in a p53-independent fashion, Oncogene 39(25): 4828-4843.
- Christodoulou, E.; Doorn, R. van; Visser, M.; Teunisse, A.; Versluis, M.; Velden, P. van der; Hayward, N.K.; Jochemsen, A. & Gruis, N. (2020), NEK11 as a candidate high-penetrance melanoma susceptibility gene, Journal of Medical Genetics 57(3): 203-210.
- Decaudin, D.; Leitz, E.F.D.; Nemati, F.; Tarin, M.; Naguez, A.; Zerara, M.; Marande, B.; Vivet-Noguer, R.; Halilovic, E.; Fabre, C.; Jochemsen, A.; Roman-Roman, S. & Alsafadi, S. (2020), Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma, European Journal of Cancer 126: 93-103.
- Nejad, E.B.; Labrie, C.; Abdulrahman, Z.; Elsas, M.J. van; Rademaker, E.; Kleinovink, J.W.; Sluis, T.C. van der; Duikeren, S. van; Teunisse, A.F.A.S.; Jochemsen, A.G.; Oosting, J.; Miranda, N.F.C.C. de; Hall, T. van; Arens, R. & Burg, S.H. van der (2020), Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy, Journal for ImmunoTherapy of Cancer 8(2).
- Salgado, C.; Kwesi-Maliepaard, E.M.; Jochemsen, A.G.; Visser, M.; Harland, M.; Leeuwen, F. van; Doorn, R. van & Gruis, N. (2019), A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma., Melanoma Research 29(6).
- Salgado, C.; Kwesi-Maliepaard, E.M.; Jochemsen, A.G.; Visser, M.; Harland, M.; Leeuwen, F. van; Doorn, R. van & Gruis, N. (2019), A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma, Melanoma Research 29(6): 582-589.
- Christodoulou, E.; Doorn, R. van; Visser, M.; Teunisse, A.; Versluis, M.; Velden, P. van der; Hayward, N.K.; Jochemsen, A. & Gruis, N. (2019), NEK11 as a candidate high-penetrance melanoma susceptibility gene, Journal of Medical Genetics 56(11).
- Dogrusoz, M.; Trasel, A.R.; Cao, J.F.; Colak, S.; Pelt, S.I. van; Kroes, W.G.M.; Teunisse, A.E.A.S.; Alsafadi, S.; Duinen, S.G. van; Luyten, G.P.M.; Velden, P.A. van der; Amaro, A.; Pfeffer, U.; Jochemsen, A.G. & Jager, M.J. (2019), Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma, Cancers 11(8).
- Souri, Z.; Wierenga, A.P.A.; Mulder, A.; Jochemsen, A.G. & Jager, M.J. (2019), HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target, Cancers 11(8).
- Souri, Z.; Wierenga, A.P.A.; Weeghel, C. van; Velden, P.A. van der; Kroes, W.G.M.; Luyten, G.P.M.; Burg, S.H. van der; Jochemsen, A.G. & Jager, M.J. (2019), Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma, Cancers 11(8).
- Rodrigues, M.; Koning, L. de; Coupland, S.E.; Jochemsen, A.G.; Marais, R.; Stern, M.H.; Valente, A.; Barnhill, R.; Cassoux, N.; Evans, A.; Galloway, I.; Jager, M.J.; Kapiteijn, E.; Romanowska-Dixon, B.; Ryll, B.; Roman-Roman, S.; Piperno-Neumann, S.; Alsafadi, S.; Deacudin, D.; Leitz, E.F.D.; Naguez, A.; Nemati, F.; Tarin, M.; Vivet-Noguer, R.; Anelli, V.; Mione, M.; Brouwer, N.J.; Nell, R.; Velden, P. van der; Wierenga, A.; Cirri, E.; Prestat, A.; Sengenes, J.; Desjardins, L.; Elas, M.; Glinkina, K.; Groenewoud, A.; Snaar-Jagalska, E.; Hascoet, P.; Rodrigues, V.P.; Houkes, L.; Heuvel, D. van den; Kalirai, H.; Traynor, M.; Lalanne, A.; Lantz, O.; Mariani, P.; Mobuchon, L.; Pires, G.N.; Plomp, D. & UM Cure 2020 Consortium (2019), So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020, Cancers 11(7).
- Heijkants, R.; Teunisse, A.; Vries, J. de; Ovaa, H. & Jochemsen, A. (2019), Selective PKC delta Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms, ACS Chemical Biology 14(1): 132-136.
- Cao, J.F.; Pontes, K.C.S.; Heijkants, R.C.; Brouwer, N.J.; Groenewoud, A.; Jordanova, E.S.; Marinkovic, M.; Duinen, S. van; Teunisse, A.F.A.S.; Verdijk, R.M.; Snaar-Jagalska, E.; Jochemsen, A.G. & Jager, M.J. (2018), Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target, Journal of Pathology 245(4): 433-444.
- Heijkants, R.C.; Nieveen, M.; Hart, K.C. 't; Teunisse, A.F.A.S. & Jochemsen, A.G. (2018), Targeting MDMX and PKC delta to improve current uveal melanoma therapeutic strategies, Oncogenesis 7.
- IJzendoorn, D.G.P. van; Forghany, Z.; Liebelt, F.; Vertegaal, A.C.; Jochemsen, A.G.; Bovee, J.V.M.G.; Szuhai, K. & Baker, D.A. (2017), Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis, Journal of Biological Chemistry 292(52): 21282-21290.
- Cao, J.F.; Heijkants, R.C.; Jochemsen, A.G.; Dogrusoz, M.; Lange, M.J. de; Velden, P.A. van der; Burg, S.H. van der; Jager, M.J. & Verdijk, R.M. (2017), Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy, Oncotarget 8(35): 58021-58036.
- Sand, L.G.L.; Buckle, T.; Leeuwen, F.W.B. van; Corver, W.E.; Kruisselbrink, A.B.; Jochemsen, A.G.; Hogendoorn, P.C.W. & Szuhai, K. (2017), Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma, BMC Cancer 17.
- Miranda, P.J.; Buckley, D.; Raghu, D.; Pang, J.M.B.; Takano, E.A.; Vijayakumaran, R.; Teunisse, A.F.A.S.; Posner, A.; Procter, T.; Herold, M.J.; Gamell, C.; Marine, J.C.; Fox, S.B.; Jochemsen, A.; Haupt, S. & Haupt, Y. (2017), MDM4 is a rational target for treating breast cancers with mutant p53, Journal of Pathology 241(5): 661-670.
- Marine, J.C. & Jochemsen, A.G. (2016), MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond, Cold Spring Harbor perspectives in medicine 6(7).
- Sand, L.G.L.; Jochemsen, A.G.; Beletkaia, E.; Schmidt, T.; Hogendoorn, P.C.W. & Szuhai, K. (2015), Novel splice variants of CXCR4 identified by transcriptome sequencing, Biochemical and Biophysical Research Communications 466(1): 89-94.
- Haupt, S.; Buckley, D.; Pang, J.M.B.; Panimaya, J.; Paul, P.J.; Gamell, C.; Takano, E.A.; Lee, Y.Y.; Hiddingh, S.; Rogers, T.M.; Teunisse, A.F.A.S.; Herold, M.J.; Marine, J.C.; Fox, S.B.; Jochemsen, A. & Haupt, Y. (2015), Targeting Mdmx to treat breast cancers with wild-type p53, Cell Death and Disease 6.
- Cao, J.F.; Verdijk, R.M.; Jochemsen, A.G. & Jager, M.J. (2015), Mitogen-activated protein kinase (MAPK) inhibitors in conjunctival melanoma cell lines, Investigative Ophthalmology & Visual Science 56(7).
- Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Jochemsen, A.G.; Simeonova, I.; Fang, M. & Toledo, F. (2015), Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity, Oncogene 34(22): 2943-2948.
- Grawenda, A.M.; Moller, E.K.; Lam, S.; Repapi, E.; Teunisse, A.F.A.S.; Alnaes, G.I.G.; Borresen-Dale, A.L.; Kristensen, V.N.; Goding, C.R.; Jochemsen, A.G.; Edvardsen, H. & Bond, G.L. (2015), Interaction between p53 Mutation and a Somatic HDMX Biomarker Better Defines Metastatic Potential in Breast Cancer.
- Lam, S.; Wiercinska, E.; Teunisse, A.F.A.S.; Lodder, K.; Dijke, P. ten & Jochemsen, A.G. (2014), Wild-type p53 inhibits pro-invasive properties of TGF-beta 3 in breast cancer, in part through regulation of EPHB2, a new TGF-beta target gene, Breast Cancer Research and Treatment 148(1): 7-18.
- Ent, W. van der; Burrello, C.; Teunisse, A.F.A.S.; Ksander, B.R.; Velden, P.A. van der; Jager, M.J.; Jochemsen, A.G. & Snaar-Jagalska, B.E. (2014), Modeling of Human Uveal Melanoma in Zebrafish Xenograft Embryos, Investigative Ophthalmology & Visual Science 55(10).
- Ent, W. van der; Jochemsen, A.G.; Teunisse, A.F.A.S.; Krens, S.F.G.; Szuhai, K.; Spaink, H.P.; Hogendoorn, P.C.W. & Snaar-Jagalska, B.E. (2014), Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53, Journal of Pathology 233(4): 415-424.
- Biswas, S.; Killick, E.; Jochemsen, A.G. & Lunec, J. (2014), The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.
- Jochemsen, A.G. (2014), Reactivation of p53 as therapeutic intervention for malignant melanoma, Current Opinion in Oncology 26(1): 114-119.
- Ent W. van der, Jochemsen A.G., Teunisse A.F., Krens S.G., Szuhai K., Spaink H.P., Hogendoorn P.C. & Snaar-Jagalska B.E. (2014), Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53, Journal of Pathology 223(4): 415-424.
- Farhang Ghahremani, M.; Goossens, S.; Nittner, D.; Bisteau, X.; Bartunkova, S.; Zwolinska, A.; Hulpiau, P.; Haigh, K.; Haenebalcke, L.; Drogat, B.; Jochemsen, A.; Roger, P.P.; Marine, J.C. & Haigh, J.J. (2013), p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway, Cell Death and Differentiation 20(7): 888-897.
- Vyas, R.; Kumar, R.; Clermont, F.; Helfricht, A.; Kalev, P.; Sotiropoulou, P.; Hendriks, I.A.; Radaelli, E.; Hochepied, T.; Blanpain, C.; Sablina, A.; Attikum, H. van; Olsen, J.V.; Jochemsen, A.G.; Vertegaal, A.C.O. & Marine, J.C. (2013), RNF4 is required for DNA double-strand break repair in vivo, Cell Death and Differentiation 20(3): 490-502.
- Nittner, D.; Lambertz, I.; Clermont, F.; Mestdagh, P.; Kohler, C.; Nielsen, S.J.; Jochemsen, A.; Speleman, F.; Vandesompele, J.; Dyer, M.A.; Schramm, A.; Schulte, J.H. & Marine, J.C. (2012), Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation, Nature Cell Biology 14(9): 958-+.
- Gembarska, A.; Luciani, F.; Fedele, C.; Russell, E.A.; Dewaele, M.; Villar, S.; Zwolinska, A.; Haupt, S.; Lange, J. de; Yip, D.; Goydos, J.; Haigh, J.J.; Haupt, Y.; Larue, L.; Jochemsen, A.; Shi, H.B.; Moriceau, G.; , R.S. lo; Ghanem, G.; Shackleton, M.; Bernal, F. & Marine, J.C. (2012), MDM4 is a key therapeutic target in cutaneous melanoma, Nature Medicine 18(8): 1239-+.
- Lenos, K.; Grawenda, A.M.; Lodder, K.; Kuijjer, M.L.; Teunisse, A.F.A.S.; Repapi, E.; Grochola, L.F.; Bartel, F.; Hogendoorn, P.C.W.; Wuerl, P.; Taubert, H.; Cleton-Jansen, A.M.; Bond, G.L. & Jochemsen, A.G. (2012), Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer, Cancer Research 72(16): 4074-4084.
- Lenos, K.; Grawenda, A.M.; Lodder, K.; Kuijjer, M.L.; Teunisse, A.F.A.S.; Repapi, E.; Grochola, L.F.; Bartel, F.; Hogendoorn, P.C.W.; Wuerl, P.; Taubert, H.; Cleton-Jansen, A.M.; Bond, G.L. & Jochemsen, A.G. (2012), Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer, Cancer Research 72(16): 4074-4084.
- Lenos, K.; Grawenda, A.M.; Lodder, K.; Kuijjer, M.L.; Teunisse, A.F.A.S.; Repapi, E.; Grochola, L.F.; Bartel, F.; Hogendoorn, P.C.W.; Wuerl, P.; Taubert, H.; Cleton-Jansen, A.M.; Bond, G.L. & Jochemsen, A.G. (2012), Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer, Cancer Research 72(16): 4074-4084.
- Dekker, P.; Gunn, D.; McBryan, T.; Dirks, R.W.; Heemst, D. van; Lim, F.L.; Jochemsen, A.G.; Verlaan-de Vries, M.; Nagel, J.; Adams, P.D.; Tanke, H.J.; Westendorp, R.G.J. & Maier, A.B. (2012), Microarray-based identification of age-dependent differences in gene expression of human dermal fibroblasts, Mechanisms of Ageing and Development 133(7): 498-507.
- Lange, J. de; Verlaan-de Vries, M.; Teunisse, A.F.A.S. & Jochemsen, A.G. (2012), Chk2 mediates RITA-induced apoptosis, Cell Death and Differentiation 19(6): 980-989.
- Lange, J. de; Verlaan-de Vries, M.; Teunisse, A.F.A.S. & Jochemsen, A.G. (2012), Chk2 mediates RITA-induced apoptosis, Cell Death and Differentiation 19(6): 980-989.
- Lange, J. de; Ly, L.V.; Lodder, K.; Verlaan-de Vries, M.; Teunisse, A.F.A.S.; Jager, M.J. & Jochemsen, A.G. (2012), Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma, Oncogene 31(9): 1105-1116.
- Jochemsen, A.G. (2012), Mdmx: A p53 activator?, Cell Cycle 11(5): 843-843.
- Jochemsen, A.G. (2012), Mdmx: A p53 activator?, Cell Cycle 11(5): 843-843.
- Lenos, K. & Jochemsen, A.G. (2011), Functions of MDMX in the Modulation of the p53-Response, Journal of Biomedicine and Biotechnology: -.
- Lenos, K.; Lange, J. de; Teunisse, A.F.A.S.; Lodder, K.; Verlaan-de Vries, M.; Wiercinska, E.; Burg, M.J.M. van der; Szuhai, K. & Jochemsen, A.G. (2011), Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts., Molecular Cancer 10: 111.
- Spinnler, C.; Hedstrom, E.; Li, H.; Lange, J. de; Nikulenkov, F.; Teunisse, A.F.A.S.; Verlaan-de Vries, M.; Grinkevich, V.; Jochemsen, A.G. & Selivanova, G. (2011), Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX, Cell Death and Differentiation 18(11): 1736-1745.
- Lenos, K.; Lange, J. de; Teunisse, A.F.A.S.; Lodder, K.; Verlaan-de Vries, M.; Wiercinska, E.; Burg, M.J.M. van der; Szuhai, K. & Jochemsen, A.G. (2011), Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts, Molecular Cancer 10: -.
- Naderi, E.H.; Jochemsen, A.G.; Blomhoff, H.K. & Naderi, S. (2011), Activation of cAMP Signaling Interferes with Stress-Induced p53 Accumulation in ALL-Derived Cells by Promoting the Interaction between p53 and HDM2, Neoplasia 13(7): 653-U110.
- Lange, J. de; Ly, L.V.; Lodder, K.; Verlaan-de Vries, M.; Teunisse, A.F.A.S.; Jager, M.J. & Jochemsen, A.G. (2011), Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma., Oncogene.
- Phillips, A.; Teunisse, A.; Lam, S.; Lodder, K.; Darley, M.; Emaduddin, M.; Wolf, A.; Richter, J.; Lange, J. de; Verlaan-de Vries, M.; Lenos, K.; Bohnke, A.; Bartel, F.; Blaydes, J.P. & Jochemsen, A.G. (2010), HDMX-L Is Expressed from a Functional p53-responsive Promoter in the First Intron of the HDMX Gene and Participates in an Autoregulatory Feedback Loop to Control p53 Activity, Journal of Biological Chemistry 285(38): 29111-29127.
- Hollestelle, A.; Nagel, J.H.A.; Smid, M.; Lam, S.; Elstrodt, F.; Wasielewski, M.; Ng, S.S.; French, P.J.; Peeters, J.K.; Rozendaal, M.J.; Riaz, M.; Koopman, D.G.; Hagen, T.L.M. ten; Leeuw, B.H.C.G.M. de; Zwarthoff, E.C.; Teunisse, A.; Spek, P.J. van der; Klijn, J.G.M.; Dinjens, W.N.M.; Ethier, S.P.; Clevers, H.; Jochemsen, A.G.; Bakker, M.A. den; Foekens, J.A.; Martens, J.W.M. & Schutte, M. (2010), Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines, Breast Cancer Research and Treatment 121(1): 53-64.
- Lam, S.; Lodder, K.; Teunisse, A.F.A.S.; Rabelink, M.J.W.E.; Schutte, M. & Jochemsen, A.G. (2010), Role of Mdm4 in drug sensitivity of breast cancer cells, Oncogene 29(16): 2415-2426.
- Reed, D.; Shen, Y.; Shelat, A.A.; Arnold, L.A.; Ferreira, A.M.; Zhu, F.Y.; Mills, N.; Smithson, D.C.; Regni, C.A.; Bashford, D.; Cicero, S.A.; Schulman, B.A.; Jochemsen, A.G.; Guy, R.K. & Dyer, M.A. (2010), Identification and Characterization of the First Small Molecule Inhibitor of MDMX, Journal of Biological Chemistry 285(14): 10786-10796.
- Boesten L.S., Zadelaar A.S., Nieuwkoop A. van, Hu L., Teunisse A.F.A.S., Jochemsen A.G., Evers B., Water B. van de, Gijbels M.J., Vlijmen B.J. van, Havekes L.M. & Winther M.P. de (2009), Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice, Atherosclerosis 207(2): 399-404.
- Boesten LSM, Zadelaar ASM, van Nieuwkoop A, Hu LH, Teunisse AFAS, Jochemsen AG, Evers B, van de Water B, Gijbels MJJ & van Vlijmen BJM (2009), Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice, Atherosclerosis 207(2): 399-404.
- Zhang XN, Lin L, Guo HR, Yang JH, Jones SN, Jochemsen A & Lu XB (2009), Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response, Cancer Research 69(20): 7960-7968.
- Schrage, Y.M.; Lam, S.; Jochemsen, A.G.; Cleton-Jansen, A.M.; Taminiau, A.H.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2009), Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro, Journal of Cellular and Molecular Medicine 13(9A): 2843-2852.
- Ohtsubo C, Shiokawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, Taya Y & Okamoto K (2009), Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2, Cancer Science 100(7): 1291-1299.
- Wang YYV, Leblanc M, Wade M, Jochemsen AG & Wahl GM (2009), Increased Radioresistance and Accelerated B Cell Lymphomas in Mice with Mdmx Mutations that Prevent Modifications by DNA-Damage-Activated Kinases, Cancer Cell 16(1): 33-43.
- Zuckerman V, Lenos K, Popowicz GM, Silberman I, Grossman T, Marine JC, Holak TA, Jochemsen AG & Haupt Y (2009), c-Abl Phosphorylates Hdmx and Regulates Its Interaction with p53, Journal of Biological Chemistry 284(6): 4031-4039.
- Brenkman AB, de Keizer PLJ, van den Broek NJF, Jochemsen AG & Burgering BMT (2008), Mdm2 Induces Mono-Ubiquitination of FOXO4, PLoS ONE 3(7): -.
- Meulmeester E & Jochemsen AG (2008), p53: A guide to apoptosis, Current Cancer Drug Targets 8(2).
- Benosman S, Gross I, Clarke N, Jochemsen AG, Okamoto K, Loeffler JP & Gaiddon C (2007), Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis, Cell Death and Differentiation 14(12).
- Marine JCW, Dyer MA & Jochemsen AG (2007), MDMX: from bench to bedside, Journal of Cell Science 120(3).
- Boesten LSM, Zadelaar SM, De Clercq S, Francoz S, van Nieuwkoop A, Biessen EAL, Hofmann F, Feil S, Feil R, Jochemsen AG, Zurcher C, Havekes LM, van Vlijmen BJM & Marine JC (2006), Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death, Cell Death and Differentiation 13(12).
- Laurie NA, Donovan SL, Shih CS, Zhang JK, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG & Dyer MA (2006), Inactivation of the p53 pathway in retinoblastoma, Nature 444(7115).
- Pereg Y, Lam S, Teunisse A, Biton S, Meulmeester E, Mittelman L, Buscemi G, Okamoto K, Taya Y, Shiloh Y & Jochemsen AG (2006), Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage, Molecular and Cellular Biology 26(18).
- Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, Prives C, Shiloh Y, Jochemsen AG & Taya Y (2005), DNA damage-induced phosphorylation of MdmX at Serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation, Molecular and Cellular Biology 25(21).
- Meulmeester E, Pereg Y, Shiloh Y & Jochemsen AG (2005), ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation, Cell Cycle 4(9).
- Marine JC & Jochemsen AG (2005), Mdmx as an essential regulator of p53 activity, Biochemical and Biophysical Research Communications 331(3).
- Meulmeester E, Maurice MM, Boutell C, Teunisse AFAS, Ovaa H, Abraham TE, Dirks RW & Jochemsen AG (2005), Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2, Molecular Cell 18(5).
- Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AFAS, Lehmann WD, Jochemsen AG & Shiloh Y (2005), Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage, Proceedings of the National Academy of Sciences 102(14).
- Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG & Marine JC (2004), Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity, Molecular and Cellular Biology 24(13).
- Marine JC & Jochemsen AG (2004), Mdmx and Mdm2 - Brothers in arms?, Cell Cycle 3(7).
- de Graaf P, Little NA, Ramos YFM, Meulmeester E, Letteboer SJF & Jochemsen AG (2003), Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2, Journal of Biological Chemistry 278(40).
- Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH & Jochemsen AG (2003), Critical role for a central part of Mdm2 in the ubiquitylation of p53, Molecular and Cellular Biology 23(14).
- Migliorini D, Denchi EL, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, Pelicci PG & Marine JC (2002), Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development, Molecular and Cellular Biology 22(15).
- Gu JJ, Kawai H, Nie LG, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G & Yuan ZM (2002), Mutual dependence of MDM2 and MDMX in their functional inactivation of p53, Journal of Biological Chemistry 277(22).
- Hattinger CM, Jochemsen AG, Tanke HJ & Dirks RW (2002), Induction of p21 mRNA synthesis after short-wavelength UV light visualized in individual cells by RNA FISH, Journal of Histochemistry and Cytochemistry 50(1).
- Gentiletti F, Mancini F, D'Angelo M, Sacchi A, Pontecorvi A, Jochemsen AG & Moretti F (2002), MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts, Oncogene 21(6).
- Little NA & Jochemsen AG (2002), p63, International Journal of Biochemistry and Cell Biology 34(1).
- Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK & Jochemsen AG (2001), Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms, EMBO Reports 2(11).
- Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG & Lozano G (2001), Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53, Nature Genetics 29(1).
- Scharnhorst V, van der Eb AJ & Jochemsen AG (2001), WT1 proteins: functions in growth and differentiation, Gene 273(2).
- Little NA & Jochemsen AG (2001), Hdmx and Mdm2 can repress transcription activation by p53 but not by p63, Oncogene 20(33).
- Ramos YFM, Stad R, Attema J, Peltenburg LTC, van der Eb AJ & Jochemsen AG (2001), Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53, Cancer Research 61(5).
- Snaar S, Wiesmeijer K, Jochemsen AG, Tanke HJ & Dirks RW (2000), Mutational analysis of fibrillarin and its mobility in living human cells, Journal of Cell Biology 151(3).